Compare SON & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SON | HAE |
|---|---|---|
| Founded | 1899 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 3.7B |
| IPO Year | N/A | 1991 |
| Metric | SON | HAE |
|---|---|---|
| Price | $44.39 | $79.45 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 9 |
| Target Price | $56.83 | ★ $88.38 |
| AVG Volume (30 Days) | ★ 886.5K | 712.4K |
| Earning Date | 02-17-2026 | 02-05-2026 |
| Dividend Yield | ★ 4.86% | N/A |
| EPS Growth | ★ 116.52 | 42.54 |
| EPS | ★ 6.30 | 3.44 |
| Revenue | ★ $7,114,053,000.00 | $1,327,850,000.00 |
| Revenue This Year | $45.34 | N/A |
| Revenue Next Year | N/A | $6.01 |
| P/E Ratio | $23.56 | ★ $23.33 |
| Revenue Growth | ★ 67.86 | N/A |
| 52 Week Low | $38.65 | $47.32 |
| 52 Week High | $50.09 | $87.32 |
| Indicator | SON | HAE |
|---|---|---|
| Relative Strength Index (RSI) | 69.19 | 53.54 |
| Support Level | $42.96 | $79.41 |
| Resistance Level | $44.10 | $81.27 |
| Average True Range (ATR) | 0.66 | 1.67 |
| MACD | 0.09 | -0.91 |
| Stochastic Oscillator | 97.01 | 14.94 |
Over its 100-year-plus history, Sonoco Products has steadily assembled a diverse portfolio of industrial and consumer packaging product offerings such as flexible and rigid plastics, reels and spools, pallets, and composite cans. The company serves a variety of consumer and industrial end markets throughout North America. Sonoco has raised its dividend each year for more than 40 years.
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.